# ZETRONE Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zetrone-co

- Industry: Biotechnology
- Headquarters: Hwaseong-si, South Korea
- Website: www.zetrone.com/
- Latest round: Seed (Oct 23, 2025)
- Investors on record: 1

## About

ZETRONE Co., Ltd., located in Hwaseong, South Korea, specializes in the integration of low-temperature plasma and AI technologies to enhance biochemical reactions and transform waste resources into valuable products.Founded in 2025 in Hwaseong, South Korea, ZETRONE Co., Ltd. focuses on leveraging innovative technologies to improve biochemical production efficiency. The company has recently engaged in a funding round on October 23, 2025, aimed at expanding its operations. The founder's history and prior ventures are not publicly detailed.ZETRONE Co., Ltd. specializes in the innovative integration of low-temperature plasma, synthetic biology, and AI technology to create high-efficiency biochemical reactions. Their core offerings focus on transforming abundant resources, such as atmospheric carbon dioxide and industrial by-product gases, into valuable biochemical products while overcoming traditional biological limitations. ZETRONE targets sectors facing significant challenges due to high production costs and inefficient processes in existing microbial fermentation methods. The company seeks to serve a diverse clientele, including industries engaged in biofuels, pharmaceuticals, and other biochemical applications, primarily in markets across North America, Europe, and Asia. By enabling the use of alternative feedstocks like waste cooking oil and biomass, ZETRONE aims to facilitate a sustainable approach to production, ensuring economic viability and environmental benefits.ZETRONE’s revenue structure is built around B2B transactions, focusing on partnerships with businesses in the biochemical and renewable energy sectors. The company engages clients through strategic collaborations that enhance its platform capabilities and drive technological advancements. Revenue generation occurs through the provision of specialized services and products derived from their proprietary technology, which significantly reduces production costs compared to traditional methods. Partnerships are structured to include milestone payments associated with research and development achievements, as well as licensing agreements for their unique bioprocessing technologies. ZETRONE's flagship offerings are expected to appeal to large-scale manufacturers looking to innovate their processes, thereby establishing a sustainable revenue stream from both initial contracts and ongoing service agreements.In October 2025, ZETRONE Co., Ltd. raised an undisclosed amount of SEED funding from new investor Bluepoint Partners. The investment will enable the company to build partnerships aimed at increasing profits through personnel and platform technology research and development. ZETRONE is targeting the introduction of new products designed to enhance biochemical processes, with plans for expansion into North America, Europe, and Asia by 2026.

## Funding rounds

- Seed, Oct 23, 2025 — Bluepoint Partners

## Investors

- Bluepoint Partners (https://capitalatlas.ai/funds/bluepoint-partners) — Seed